{
}
Darwin Wealth Management LLC and Elkhorn Partners Limited Partnership recently acquired new positions in CRISPR Therapeutics, with investments of approximately $43,000 and $54,000, respectively. Hedge funds and institutional investors own 69.20% of the stock, which has a "Hold" rating among analysts, with a consensus price target of $78.38. CEO Samarth Kulkarni sold 15,000 shares for $826,500, reducing his ownership by 7.63%.
Geode Capital Management LLC increased its stake in CRISPR Therapeutics, now holding over 1 million shares valued at $47.4 million. Institutional investors own 69.20% of the stock, while CRISPR's recent performance includes a new 52-week low of $36.70. Analysts maintain a "Hold" rating, with an average price target of $78.38.
CRISPR Therapeutics, trading at $39.69 with a market cap of $3.39 billion, is focusing on the launch of its gene-based medicine CASGEVY® and advancing its gene editing pipeline. The company reported operating expenses of $110.1 million and a cash position of $1.94 billion, while analysts hold mixed ratings. Key developments include ongoing clinical trials for CTX112™ and CTX131™, with updates expected in 2025, alongside a strong demand for CASGEVY® following its regulatory approval for sickle cell disease and beta thalassemia.
CRISPR Therapeutics is poised for a significant year in 2025, building on the successful launch of CASGEVY, which has seen strong global demand and payer support. With a robust pipeline and approximately $1.9 billion in cash, the company plans to advance key candidates in oncology, autoimmune, and cardiovascular diseases, while continuing to innovate in gene editing technologies. The recent regulatory approval of CASGEVY in the UAE highlights its transformative potential for treating sickle cell disease and beta thalassemia.
State Street Corp has increased its stake in CRISPR Therapeutics to nearly 3 million shares, valued at $140.6 million. CEO Samarth Kulkarni and General Counsel James R. Kasinger recently sold shares, reducing their holdings. Analysts maintain a "Hold" rating on the stock, with a consensus price target of $78.38.
CRISPR Therapeutics experienced a 1.86% decrease in insider ownership following recent stock sales totaling over $2.7 million. Institutional investors hold 69.20% of the company, with Bank of America lowering its price target to $85, indicating a potential upside of 100.61%. The stock currently has a "Hold" rating among analysts, with a consensus target price of $78.38.
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, Morrison brings extensive experience in clinical development, having overseen the approval of several notable drugs. He expressed enthusiasm for joining the innovative company and contributing to its mission of developing transformative gene-based medicines.
[SEC](https://www.sec.gov) or [Bloomberg]
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, Morrison's expertise in clinical development is expected to enhance the company's innovative gene-based medicine initiatives. CRISPR Therapeutics, which celebrated the approval of the first CRISPR-based therapy in 2023, continues to advance its diverse portfolio targeting serious diseases.
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, including leadership roles at AstraZeneca and Pfizer, Morrison's expertise in clinical development is expected to enhance the company's innovative pipeline. He has overseen the development of notable drugs such as Tagrisso®, Imfinzi®, and Lynparza®.
Samarth Kulkarni
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
crisper therapeutics attracts institutional investment amid mixed analyst ratings
14:25 14.01.2025
crisper therapeutics faces challenges as stock hits new 12 month low
19:59 13.01.2025
CRISPR Therapeutics sets ambitious 2025 goals amid strong market presence
United States Dollar
Vertex Pharmaceuticals Inc
CRISPR Therapeutics AG
CHE
Briggs Morrison
Samarth Kulkarni
13:10 13.01.2025
CRISPR Therapeutics outlines strategic goals and milestones for 2025
13:00 13.01.2025
state street increases stake in crispr therapeutics amid insider stock sales
13:18 09.01.2025
insider sales and institutional investments impact crisper therapeutics stock performance
19:33 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors
United States Dollar
Pfizer Inc.
AstraZeneca PLC
CRISPR Therapeutics AG
Merck & Co., Inc.
USA
Briggs Morrison
Samarth Kulkarni
Show more
14:04 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors appointment
14:00 07.01.2025
CRISPR Therapeutics nominates Briggs Morrison for Board of Directors position
14:00 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors election
United States Dollar
Vertex Pharmaceuticals Inc
AstraZeneca PLC
Bayer AG
Pfizer Inc.
Syndax Pharmaceuticals, Inc.
Merck & Co., Inc.
CHE
Briggs Morrison
Samarth Kulkarni
Show more
14:00 07.01.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Global Trade Developments
Global Financial Events
Banking Regulations
Central Bank Actions
Retail and Consumer Goods
Finance Mergers & Acquisitions
Startups & Entrepreneurship
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Government Economic Policies
CEO Changes
Domestic Politics
Market Analysis and Predictions
Workplace Trends
Government Policies
Supply Chain Management
GDP Growth & Recession Forecasts
Countries:
Companies:
Tesla, Inc.
Apple Inc.
Barclays PLC
JPMorgan Chase & Co.
Deutsche Bank Money Market PP
Credit Suisse Strategic Income I
The Goldman Sachs Group, Inc.
Berkshire Hathaway Inc.
UBS Group AG
BNP Paribas SA
Banco Santander, S.A.
Lloyds Banking Group plc
SpaceXCoin USD
Bank of America Corporation
NVIDIA Corporation
Jenoptik AG
Air France-KLM
Amazon.com, Inc.
Wells Fargo & Company
Bank Frick AG
Currencies:
United States Dollar
Euro
Swiss Franc
British Pound Sterling
Japanese Yen
Indian Rupee
Chinese Yuan
Canadian Dollar
Vietnamese Đồng
South Korean Won
Australian Dollar
Thai Baht
Indonesian Rupiah
Singapore Dollar
Mexican Peso
Hong Kong Dollar
Offshore Chinese Yuan
New Zealand Dollar
Cambodian Riel
Myanmar Kyat
People: